论文部分内容阅读
目的:观察长春瑞滨联合卡铂治疗晚期食管癌的临床疗效及不良反应。方法:长春瑞滨25 mg/m2,第1~8天;卡铂300 mg/m2第1天。结果:治疗组36例,获得CR 2例,PR 14例,有效率(CR+PR)为44.2%,未出现III、IV度的胃肠道反应。结论:长春瑞滨联合卡铂治疗晚期食管癌的临床疗效高于DF方案,且不良反应尤其是胃肠道反应明显降低,值得临床进一步研究。
Objective: To observe the clinical efficacy and adverse reactions of vinorelbine plus carboplatin in the treatment of advanced esophageal cancer. Methods: Vinorelbine 25 mg / m2, days 1 to 8; carboplatin 300 mg / m2 on day 1. Results: In the treatment group, 36 cases received CR 2 cases and PR 14 cases, and the effective rate (CR + PR) was 44.2%. No III and IV gastrointestinal reactions occurred. CONCLUSION: The clinical efficacy of vinorelbine plus carboplatin in the treatment of advanced esophageal cancer is higher than that of the DF regimen. Adverse reactions, especially gastrointestinal reactions, are significantly reduced and deserve further clinical study.